Procept Biorobotics Corp Stock Analysis

PRCT Stock  USD 28.12  0.33  1.19%   
Below is the normalized historical share price chart for Procept Biorobotics Corp extending back to September 15, 2021. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Procept Biorobotics stands at 28.12, as last reported on the 18th of February 2026, with the highest price reaching 28.59 and the lowest price hitting 27.50 during the day.
IPO Date
15th of September 2021
200 Day MA
41.9633
50 Day MA
31.79
Beta
0.985
 
Covid
 
Interest Hikes
Procept Biorobotics Corp holds a debt-to-equity ratio of 0.23. At this time, Procept Biorobotics' Short Term Debt is comparatively stable compared to the past year. Interest Debt Per Share is likely to gain to 1.50 in 2026, whereas Long Term Debt is likely to drop slightly above 49.8 M in 2026. Procept Biorobotics' financial risk is the risk to Procept Biorobotics stockholders that is caused by an increase in debt.

Asset vs Debt

Equity vs Debt

Procept Biorobotics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Procept Biorobotics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Procept Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Procept Biorobotics' stakeholders.
For many companies, including Procept Biorobotics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Procept Biorobotics Corp, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Procept Biorobotics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
4.0843
Enterprise Value Ebitda
(24.58)
Price Sales
5.1778
Shares Float
53.8 M
Wall Street Target Price
50.7273
At this time, Procept Biorobotics' Total Stockholder Equity is comparatively stable compared to the past year. Other Stockholder Equity is likely to gain to about 1.1 B in 2026, whereas Common Stock is likely to drop (318.5 M) in 2026. . At this time, Procept Biorobotics' Price Book Value Ratio is comparatively stable compared to the past year. Price Earnings To Growth Ratio is likely to gain to 1.98 in 2026, whereas Price To Operating Cash Flows Ratio is likely to drop (51.08) in 2026.
Procept Biorobotics Corp is undervalued with Real Value of 32.65 and Target Price of 50.73. The main objective of Procept Biorobotics stock analysis is to determine its intrinsic value, which is an estimate of what Procept Biorobotics Corp is worth, separate from its market price. There are two main types of Procept Biorobotics' stock analysis: fundamental analysis and technical analysis.
The Procept Biorobotics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Procept Biorobotics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Procept Stock trading window is adjusted to America/New York timezone.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Procept Biorobotics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services.

Procept Stock Analysis Notes

About 96.0% of the company shares are owned by institutional investors. The book value of Procept Biorobotics was at this time reported as 6.81. The company recorded a loss per share of 1.53. Procept Biorobotics Corp had not issued any dividends in recent years. PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California. Procept Biorobotics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 234 people. To find out more about Procept Biorobotics Corp contact Larry Wood at 650 232 7200 or learn more at https://www.procept-biorobotics.com.

Procept Biorobotics Quarterly Total Revenue

83.33 Million

Procept Biorobotics Corp Investment Alerts

Procept Biorobotics had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 224.5 M. Net Loss for the year was (91.41 M) with profit before overhead, payroll, taxes, and interest of 193.58 M.
Procept Biorobotics Corp currently holds about 269.81 M in cash with (99.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.05.
Over 96.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: Wall Street Has a Positive Opinion on PROCEPT BioRobotics , Heres Why

Procept Largest EPS Surprises

Earnings surprises can significantly impact Procept Biorobotics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-08-04
2022-06-30-0.48-0.430.0510 
2025-07-30
2025-06-30-0.4125-0.350.062515 
2022-05-05
2022-03-31-0.47-0.390.0817 
View All Earnings Estimates

Procept Biorobotics Environmental, Social, and Governance (ESG) Scores

Procept Biorobotics' ESG score is a quantitative measure that evaluates Procept Biorobotics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Procept Biorobotics' operations that may have significant financial implications and affect Procept Biorobotics' stock price as well as guide investors towards more socially responsible investments.

Procept Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Artisan Partners Limited Partnership2025-06-30
986.3 K
Baillie Gifford & Co Limited.2025-06-30
876.4 K
Axa Sa2025-06-30
850.5 K
Bnp Paribas Investment Partners Sa2025-06-30
784.2 K
Jpmorgan Chase & Co2025-06-30
765 K
Mackenzie Investments2025-06-30
708.7 K
Mirae Asset Global Etfs Holdings Ltd.2025-06-30
687.7 K
Bank Of America Corp2025-06-30
625.7 K
Wellington Management Company Llp2025-06-30
615.2 K
Fmr Inc2025-06-30
7.8 M
Vanguard Group Inc2025-06-30
5.2 M
Note, although Procept Biorobotics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Procept Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.55 B.

Procept Profitablity

The company has Profit Margin (PM) of (0.28) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.28) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.28.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.15)(0.16)
Return On Capital Employed(0.18)(0.19)
Return On Assets(0.15)(0.16)
Return On Equity(0.20)(0.21)

Management Efficiency

Procept Biorobotics Corp has return on total asset (ROA) of (0.1306) % which means that it has lost $0.1306 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2722) %, meaning that it created substantial loss on money invested by shareholders. Procept Biorobotics' management efficiency ratios could be used to measure how well Procept Biorobotics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.16 in 2026. Return On Capital Employed is likely to drop to -0.19 in 2026. At this time, Procept Biorobotics' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 7 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 31.5 M in 2026.
Last ReportedProjected for Next Year
Book Value Per Share 6.94  4.92 
Tangible Book Value Per Share 6.93  4.88 
Enterprise Value Over EBITDA(55.31)(58.08)
Price Book Value Ratio 12.00  18.47 
Enterprise Value Multiple(55.31)(58.08)
Price Fair Value 12.00  18.47 
Enterprise Value1.6 B1.4 B
Procept Biorobotics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Operating Margin
(0.28)
Profit Margin
(0.28)
Beta
0.985
Return On Assets
(0.13)
Return On Equity
(0.27)

Technical Drivers

As of the 18th of February 2026, Procept Biorobotics holds the Risk Adjusted Performance of (0.02), coefficient of variation of (3,474), and Variance of 12.74. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Procept Biorobotics, as well as the relationship between them.

Procept Biorobotics Corp Price Movement Analysis

Execute Study
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Procept Biorobotics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Procept Biorobotics Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Procept Biorobotics Corp Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Procept Biorobotics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Procept Biorobotics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Procept Biorobotics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Alaleh Nouri 3 days ago
Acquisition by Alaleh Nouri of 11000 shares of Procept Biorobotics at 4.52 subject to Rule 16b-3
 
Prescott Thomas M over three months ago
Acquisition by Prescott Thomas M of 1538 shares of Procept Biorobotics subject to Rule 16b-3
 
Alaleh Nouri over six months ago
Disposition of 11000 shares by Alaleh Nouri of Procept Biorobotics at 4.52 subject to Rule 16b-3
 
Desai Antal Rohit over six months ago
Disposition of 5049 shares by Desai Antal Rohit of Procept Biorobotics at 62.3277 subject to Rule 16b-3
 
Desai Antal Rohit over six months ago
Disposition of 5717 shares by Desai Antal Rohit of Procept Biorobotics at 64.2727 subject to Rule 16b-3
 
Prescott Thomas M over six months ago
Acquisition by Prescott Thomas M of 2771 shares of Procept Biorobotics at 64.23 subject to Rule 16b-3
 
Hisham Shiblaq over six months ago
Disposition of 20000 shares by Hisham Shiblaq of Procept Biorobotics at 5.18 subject to Rule 16b-3
 
Moll Frederic H over six months ago
Disposition of 5263 shares by Moll Frederic H of Procept Biorobotics at 0.86 subject to Rule 16b-3
 
Alaleh Nouri over six months ago
Disposition of 316 shares by Alaleh Nouri of Procept Biorobotics at 57.06 subject to Rule 16b-3
 
Desai Antal Rohit over six months ago
Disposition of 100 shares by Desai Antal Rohit of Procept Biorobotics at 78.91 subject to Rule 16b-3
 
Reza Zadno over six months ago
Disposition of 15916 shares by Reza Zadno of Procept Biorobotics at 61.31 subject to Rule 16b-3
 
Moll Frederic H over a year ago
Disposition of 5263 shares by Moll Frederic H of Procept Biorobotics at 0.86 subject to Rule 16b-3

Procept Biorobotics Outstanding Bonds

Procept Biorobotics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Procept Biorobotics Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Procept bonds can be classified according to their maturity, which is the date when Procept Biorobotics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Procept Biorobotics Predictive Daily Indicators

Procept Biorobotics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Procept Biorobotics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Procept Biorobotics Corporate Filings

13A
17th of February 2026
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
13A
11th of February 2026
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
13A
8th of January 2026
An amended filing to the original Schedule 13G
ViewVerify
13A
14th of November 2025
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
10Q
5th of November 2025
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
4th of November 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
18th of September 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
4th of September 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Procept Biorobotics Forecast Models

Procept Biorobotics' time-series forecasting models are one of many Procept Biorobotics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Procept Biorobotics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Procept Biorobotics Bond Ratings

Procept Biorobotics Corp financial ratings play a critical role in determining how much Procept Biorobotics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Procept Biorobotics' borrowing costs.
Piotroski F Score
6
HealthyView
Beneish M Score
(3.19)
Unlikely ManipulatorView

Procept Biorobotics Corp Debt to Cash Allocation

Procept Biorobotics Corp currently holds 80.25 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Procept Biorobotics Corp has a current ratio of 15.69, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Procept Biorobotics' use of debt, we should always consider it together with its cash and equity.

Procept Biorobotics Total Assets Over Time

Procept Biorobotics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Procept Biorobotics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Procept Biorobotics Debt Ratio

    
  29.0   
It appears most of the Procept Biorobotics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Procept Biorobotics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Procept Biorobotics, which in turn will lower the firm's financial flexibility.

Procept Biorobotics Corporate Bonds Issued

Procept Short Long Term Debt Total

Short Long Term Debt Total

67.62 Million

At this time, Procept Biorobotics' Short and Long Term Debt Total is comparatively stable compared to the past year.

About Procept Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Procept Biorobotics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Procept shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Procept Biorobotics. By using and applying Procept Stock analysis, traders can create a robust methodology for identifying Procept entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.37)(0.38)
Operating Profit Margin(0.39)(0.41)
Net Loss(0.37)(0.38)
Gross Profit Margin 0.55  0.58 

Current Procept Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Procept analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Procept analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceConsensus# of Analysts
50.73Strong Buy10Odds
Procept Biorobotics Corp current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Procept analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Procept stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Procept Biorobotics Corp, talking to its executives and customers, or listening to Procept conference calls.
Procept Analyst Advice Details

Procept Stock Analysis Indicators

Procept Biorobotics Corp stock analysis indicators help investors evaluate how Procept Biorobotics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Procept Biorobotics shares will generate the highest return on investment. By understating and applying Procept Biorobotics stock analysis, traders can identify Procept Biorobotics position entry and exit signals to maximize returns.
Begin Period Cash Flow260.3 M
Total Stockholder Equity402.2 M
Capital Lease Obligations28.8 M
Property Plant And Equipment Net45.6 M
Cash And Short Term Investments333.7 M
Cash333.7 M
50 Day M A31.79
Net Interest Income6.7 M
Total Current Liabilities53.1 M
Investments-4.4 M
Interest Expense4.2 M
Stock Based Compensation31.8 M
Long Term Debt51.5 M
Common Stock Shares Outstanding52.1 M
Total Cashflows From Investing Activities-4.4 M
Free Cash Flow-103.6 M
Other Current Assets8.5 M
Accounts Payable10 M
Net Debt-253.5 M
Other Operating Expenses321.1 M
Non Current Assets Total52.2 M
Liabilities And Stockholders Equity534 M
Non Currrent Assets Other2.6 M

Additional Tools for Procept Stock Analysis

When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.